Randomized controlled study of Autologous Cultured Epithelium Grafting for Treatment of Vitiligo

Study of Autologous Cultured Epithelium Grafting for Treatment of Vitiligo

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100053614

Enrollment

Unknown

Registered

2021-11-25

Start date

2021-09-06

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vitiligo

Interventions

A:Autologous Cultured Epithelium Grafting

B:epidermal suction blister grafting

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. In patients with stable vitiligo, the stable period is defined as no new skin lesions, no expansion of the original skin lesions and no isomorphic reaction within at least 1 year, and the clinical non-surgical treatment is ineffective; 2. Aged from 18 to 65 years; 3. The treatment target skin lesion area is 0.25% - 1% , excluding hand, foot and scalp; 4. Sign informed consent and be willing to accept surgical treatment.

Exclusion criteria

Exclusion criteria: 1. Patients with scar constitution; 2. Patients who cannot cooperate with the operation; 3. Patients with serious medical diseases or infectious diseases who are not suitable for traumatic operation; 4. Pregnancy women; 5. Recently participated in other clinical studies.

Design outcomes

Primary

Measure	Time frame
repigment rate;	—

Countries

China

Contacts

Public ContactLI JIAN

Huashan Hospital of Fudan University

li13579_nn@qq.com+86 13817637673

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026